Phoenix Neurological Associates, Ltd.
5090 N. 40th Street
Suite 250
Phoenix, AZ 85018

Phone: (602) 258-3354
Fax: (602) 258-3368

email Phoenix Neurological Associates (If you have an urgent medical issue, do not email; please call us instead.)

news

Dr. Payne’s Team Saves Employee. Read more and watch the video

Phoenix Neurological Associates, LTD was just named one of seven international centers of Excellence for Guillan Barre and CIDP. Read more

BITE NITE 2010
Our first fundraiser took place on June 5, 2010 at Scottsdale Resort and Conference Center. PNA Center for Neurological Research teamed up with the ALS Association Arizona Chapter to co-host a night dedicated to ALS (Lou Gehrig’s Disease). BITE NITE consisted of 5 top Valley Restaurants, 5th and Wine, Cien Agaves Tacos & Tequila, Oregano's Pizza Bistro and Va Bene who served up samplers of their best dishes, with great entertainment by our favorite local band Dearspeak, with silent and live auctions. The night was an absolute blast and a success. People enjoyed great food while enjoying each other’s company for a night that was dedicated to funding ALS research. Thank you for everyone who truly made this night a success. Due to the positive praise and feedback, BITE NITE will be an annual event, so if you weren’t able to attend, we look forward to seeing you there next year! Thanks again for your support, dedication and contributions, we couldn’t have made this night possible without you.

Check out photos from BITE NITE here.

Share |


Ceftriaxone in Patients with ALS

Trial Status
Open for Enrollment

What is the Purpose of this Study?
To determine the pharmacokinetics, safety and tolerability of long term cefriaxone treatment as well as to ascertain whether chronic treatment with ceftriaxone prolongs survival in patients with ALS.

Who is Eligible to Participate?
Patients 18 years or older with familial or sporadic ALS. Patients will also have to meet all exclusionary criteria which will be explained in greater detail by the study coordinator.

What is involved in this Study?
Patients 18 years or older with familial or sporadic ALS. Patients may be on riluzole, but have to be on a stable dose for at least 30 days prior to screening. Patients will also have to meet all exclusionary criteria which will be explained in greater detail by the study coordinator.

How long is the Study?
The study will be approximately 52 weeks long.           

For More Information Contact: Nicole C. Hank, MHSM, study coordinator, at 602-258-3354 ext 137 or nhank@pnal.net or call the Main line at 602-258-3354